YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Entera Bio Ltd. Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:…
Medical research testing ©rawpixel Entera Bio Ltd. (NASDAQ:ENTX) shares fell 1.05% in pre-market trading after the clinical-stage biotechnology company reported a larger-than-expected second-quarter loss as spending increased ahead of a pi…
(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further,…
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Priv…
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be par…
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi…
(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biotechnology company developing oral peptide therapies, Monday announced a securities purchase agreement for an oversubscribed private placement expected to generate approximately $275…
Entera Bio ENTX shares have rallied about 34.5% over the past month, driven by investor optimism after the company received positive FDA feedback on the phase III registrational study design for EB613, its lead candidate for postmenopausal…
(RTTNews) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to b…
Last Friday, the three major Wall Street indexes closed a mixed week. While the Dow Jones Industrial Average managed a 0.6% progress, the S&P 500 and the Nasdaq fell 2.1% and 4.7% respectively. The sharp selloff in technology stocks follow…
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB61…
Entera Bio Ltd. EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a fi…
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class dua…
Entera Bio Ltd. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable PK…
* Entera Bio press release [https://seekingalpha.com/pr/20508125-entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q1 GAAP EPS of -$0.07 beats by $0.02…
Entera Bio Ltd. EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR E…
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first…
(RTTNews) - Entera Bio Ltd. (ENTX) , a clinical-stage company, announced that it has entered into a securities purchase agreement for a private placement led by funds affiliated with BVF Partners L.P under which the company agreed to issue…
* Entera Bio (ENTX [https://seekingalpha.com/symbol/ENTX]) said [https://seekingalpha.com/pr/20460875-entera-bio-announces-pricing-of-10_0-million-direct-investment-by-bvf-partners-with-potential] on Thursday it had entered into a securiti…
Entera Bio EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026…
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the…
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following succes…
Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and settled on a $3 price target. The positive…
Entera Bio New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 TEL AVIV…
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replaceme…
This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) ap…
(RTTNews) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical and financial milestones. China SXT Pharmaceutica…
JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Offi…
* Entera Bio press release [https://seekingalpha.com/pr/20308640-entera-bio-announces-third-quarter-2025-financial-results-and-business-updates] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q3 GAAP EPS of $0.07. * Research and developmen…
Entera Bio FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortic…
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Ind…
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic treatment option th…
Entera Bio First-time presentation examining bone outcomes in early postmenopausal women JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement thera…
JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB…
Entera Bio Ltd. ENTX recently reported encouraging pharmacokinetic data, underscoring the potential of its first-in-class oral GLP-2 analog therapy for patients with short bowel syndrome (SBS). The findings, presented at the 47th European…
Entera Bio Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,00…